Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/3/16 → 10/2/17 |
Funding
- Merck Sharp and Dohme Limited Liability Corporation: $18,750.00
A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM)
- Pan, Dorothy (PI)
Project: Research